This research validates reintroducing BGCs to activate silent pathways for discovering novel bioactive compounds.
values of 27.23 ± 1.69 μM and 61.65 ± 1.37 μM, respectively. Overall, this work validates that reintroduction of endogenous BGCs represents a robust genome mining approach to activate silent metabolic pathways and accelerate the discovery of bioactive novel natural products.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: